2022-11-14
[HONG KONG, November 14, 2022] The second Asia Summit on Global Health was held in Hong Kong on November 10, 2022, co-organised with the Government of the Hong Kong Special Administrative Region (HKSAR) and the 13th Hong Kong International Medical and Healthcare Fair. John Lee, Hong Kong SAR (HKSAR) Chief Executive, spoke at the summit’s opening ceremony, along with Margaret Fong, Executive Director of the HKTDC, Zsuzsanna Jakab, Deputy Director-General of World Health Organization (WHO); and Cao Xuetao, Vice-Minister of the National Health Commission of the People's Republic of China.

With the theme of “Charting a New Course in Healthcare through Collaboration”, more than 70 speakers from Japan, South Korea, Israel and other countries in the field of healthcare, representatives of international organizations, representatives of business circles and heads of relevant fields delivered speeches. More than 80 business leaders in the healthcare industry, scientific research professionals, healthcare officials and professional service providers, as well as more than 20,000 participants both in-person and online session discussed the opportunities and development of the global healthcare industry.

In addition, Dr. Kane Qi, Chief Commercial Officer of GBB, attended the ASGH - Shanghai-Hong Kong Cooperation Transition and 2022 Shanghai-Hong Kong Industry-Medical Integration Conference, and gave a speech entitled "Accelerating Bioprocessing Development through AI Technology".

Asia Summit on Global Health (ASGH) brings together all the stakeholders - from healthcare experts to renowned academia and influential business leaders, together with key industry players, innovative start-ups, investors and policymakers from around the world to exchange insights, explore opportunities and collaborate on the diverse and dynamic healthcare sector.

Accepted for Both Oral Presentation and Poster! Two Great Bay Bio Technology Advancements Enabling Antibody R&D for Obesity Targets Selected for Obesity Week® 2026
2026-08-12

AlfaCell Platform Enables Client’s Out-Licensed Pipeline to Successfully Enter Phase II Clinical Trials, Advancing Novel Drugs and Biosimilars in Parallel
2026-08-07

Platform Case | AI Tackles Challenging GPCR Drug Target in 8 Months! AlfaBodY Platform of Great Bay Bio Generates Long-Acting Non-Rebound Weight-Loss Antibody; Research Findings Published
2026-07-17